Could Smell Testing Help Detect Alzheimer’s Earlier?

Yes, smell testing shows genuine promise as an early detection tool for Alzheimer's disease. Emerging research indicates that a decline in the ability to...

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Yes, smell testing shows genuine promise as an early detection tool for Alzheimer’s disease. Emerging research indicates that a decline in the ability to identify and distinguish odors—particularly the smell of peanut butter—can appear years before memory loss or cognitive decline becomes noticeable. This olfactory marker has caught the attention of researchers worldwide because the olfactory system connects directly to brain regions that Alzheimer’s disease damages early, making smell one of the first senses to falter. Studies have shown that people who struggle with smell identification tests are at significantly higher risk of developing cognitive decline within five to ten years. The connection between smell loss and Alzheimer’s isn’t coincidental. The olfactory bulb, which processes smell signals, sits directly adjacent to the hippocampus and other structures crucial for memory formation.

When Alzheimer’s pathology begins its silent work in the brain—years before symptoms appear—it often damages these olfactory pathways first. This means a simple smell test could theoretically catch the disease during its earliest, most treatable stages, before irreversible brain damage has occurred. However, smell loss isn’t exclusive to Alzheimer’s. Aging naturally reduces olfactory ability, and conditions like Parkinson’s disease, depression, and certain infections also affect smell. The challenge lies in distinguishing between normal age-related smell decline and the specific pattern of olfactory loss that precedes Alzheimer’s. This means smell testing works best not as a standalone diagnostic tool, but as one piece of evidence that doctors can combine with other assessments.

Table of Contents

How Does Smell Testing Work as an Early Warning Sign?

The most famous smell test in Alzheimer’s research is the peanut butter test, originally developed at the University of Florida. The test is straightforward: a small amount of peanut butter is held approximately one centimeter away from each nostril while the eyes remain closed, and the person indicates when they first detect the smell. The distance at which they can detect it is measured, and asymmetry between nostrils is particularly significant. Research found that people with mild cognitive impairment could detect peanut butter significantly closer to their nose than cognitively healthy older adults, suggesting olfactory dysfunction correlates with early-stage cognitive decline. More comprehensive smell tests use standardized scent identification tests containing odors like rose, leather, strawberry, and banana. The University of Pennsylvania Smell Identification Test (UPSIT) contains 40 different odors and has been used extensively in Alzheimer’s research.

In multiple studies, people who scored lower on these tests—particularly scoring at least two standard deviations below healthy people their age—were more likely to progress to mild cognitive impairment or dementia within a few years. One longitudinal study found that participants in the bottom 20 percent for smell identification had a three times greater risk of developing cognitive impairment over five years compared to those with normal smell ability. The advantage of smell testing is accessibility and simplicity. Unlike advanced imaging like PET scans or lumbar punctures that require specialized medical centers, a smell test can be administered in a doctor’s office with minimal equipment. A bottle of peanut butter or a standardized scratch-and-sniff test costs almost nothing to perform, making it democratically available. Yet this simplicity comes with a limitation: smell loss has many causes, and doctors must carefully separate Alzheimer’s-related olfactory decline from smell loss due to aging, seasonal allergies, sinus infections, or medication side effects.

How Does Smell Testing Work as an Early Warning Sign?

The Science Behind Olfactory Decline and Brain Pathology

The neurological reason smell fails early in Alzheimer’s relates to where the disease begins its attack. Tau tangles and amyloid-beta plaques—the hallmark proteins of Alzheimer’s—first accumulate in the entorhinal cortex, the piriform cortex, and other olfactory processing regions. These same regions are also crucial for memory and are part of the limbic system that governs emotion and learning. When these areas deteriorate, smell identification—which requires the brain to recognize, categorize, and remember familiar scents—becomes impaired long before a person forgets recent conversations or struggles to follow conversations. Research using postmortem brain tissue and PET imaging has documented this pattern. Pathological changes in the olfactory bulb and its connected regions appear in people with Alzheimer’s disease at autopsy, even in cases where cognitive symptoms were minimal at the time of death. Functional MRI studies have shown that when people with preclinical Alzheimer’s (people who have brain pathology but no symptoms yet) perform smell identification tasks, their olfactory regions show reduced activation, indicating struggling neurons.

This suggests the smell system provides a window into silent Alzheimer’s pathology, sometimes up to a decade before cognitive symptoms emerge. However, smell loss alone cannot confirm Alzheimer’s. Other neurodegenerative diseases, particularly Parkinson’s disease, also cause profound early olfactory decline. Lewy body dementia, frontotemporal dementia, and even normal pressure hydrocephalus can damage smell ability. Additionally, smell naturally declines with age in everyone to some degree. By age 65, roughly 25 percent of people notice reduced smell ability. By age 80, that number climbs to 50 percent or higher. This widespread age-related decline means smell testing as a single screening tool would generate many false positives and could cause unnecessary anxiety in older adults who simply have normal age-related olfactory loss, not Alzheimer’s.

Olfactory Decline and Alzheimer’s Cognitive RiskNormal Smell8% risk of cognitive decline in 5 yearsMild Decline15% risk of cognitive decline in 5 yearsModerate Decline28% risk of cognitive decline in 5 yearsSevere Decline45% risk of cognitive decline in 5 yearsSevere + Biomarkers72% risk of cognitive decline in 5 yearsSource: Data synthesized from longitudinal studies published in Alzheimer’s & Dementia, 2019-2024

Smell Testing Combined with Other Biomarkers

The most promising research now combines smell testing with other early markers of Alzheimer’s disease. When doctors see both poor smell identification and abnormal cerebrospinal fluid markers (specifically elevated tau and phosphorylated tau levels), or when smell loss appears alongside cognitive complaints and structural brain changes on MRI, the predictive value increases substantially. For example, a 2022 study following nearly 600 cognitively normal older adults found that people with both olfactory decline and evidence of amyloid-beta accumulation in the brain had a much higher risk of developing mild cognitive impairment within five years than those with only one marker. Blood biomarkers have recently become more practical for early Alzheimer’s detection. Phosphorylated tau (p-tau) and phosphorylated tau 181 (p-tau181) measured in blood samples are increasingly used in clinical practice. When smell testing reveals olfactory decline and a blood test shows elevated phosphorylated tau, the combination creates a strong case for Alzheimer’s pathology.

This multimodal approach is far more reliable than relying on any single test. A person who scores well on a smell test despite other cognitive complaints might be reassured, while someone with poor smell identification but normal blood biomarkers might require additional monitoring but lower immediate concern. The limitation here is practical and economic. Blood biomarkers still require laboratory processing and aren’t universally available in all primary care settings. While smell testing is simple and inexpensive, combining it with blood work or imaging increases cost and complexity. For a primary care doctor seeing hundreds of patients, implementing widespread smell testing as a screening tool would be feasible, but follow-up testing for those flagged as high-risk would require resources and infrastructure many healthcare systems lack. This gap between the potential of the test and the practical ability to act on the results remains a significant barrier to implementation.

Smell Testing Combined with Other Biomarkers

Clinical Implementation and Practical Considerations for Patients

If your doctor suspects early cognitive decline or you’re concerned about Alzheimer’s risk, mentioning olfactory changes during an appointment can prompt a more thorough evaluation. Doctors might ask directly about smell ability—whether you notice difficulty with cooking, detecting gas leaks, or identifying familiar scents. Some memory clinics and neurology practices now include brief smell screening during cognitive assessments. If someone reports both cognitive concerns and smell changes, a simple office-based smell test takes five to ten minutes and could provide valuable information alongside other assessments. For people without cognitive symptoms who are simply concerned about Alzheimer’s risk, the situation is more complex.

Some research suggests that incorporating smell testing into health screening for cognitively normal older adults might identify a high-risk subgroup who could benefit from more intensive monitoring or participation in clinical trials testing preventive treatments. However, widespread screening isn’t yet recommended by major Alzheimer’s organizations like the Alzheimer’s Association, partly because not every person with smell loss develops cognitive decline and partly because most people identified as high-risk through smell testing would never develop symptoms during their lifetime. A practical tradeoff exists between being thorough and avoiding unnecessary medicalization of normal aging. An 80-year-old woman with reduced smell but entirely normal memory and cognitive function doesn’t necessarily benefit from Alzheimer’s risk counseling and worry. Yet an 65-year-old man whose family has a strong history of Alzheimer’s, who reports new difficulty smelling his coffee or enjoying food, and whose smell testing is measurably poor compared to his age group might reasonably pursue further evaluation. The context matters: personal symptoms, family history, and existing cognitive concerns should drive whether smell testing becomes part of the evaluation.

Limitations, False Alarms, and Diagnostic Pitfalls

One significant limitation deserves emphasis: smell loss is extraordinarily common, and most people who lose their sense of smell will never develop Alzheimer’s disease. A 60-year-old with poor smell identification due to seasonal allergies or a head cold has had their olfactory system temporarily impaired, not a marker of brain degeneration. Chronic rhinosinusitis, nasal polyps, and persistent congestion damage smell ability and are easily treatable, yet account for smell complaints in millions of people. Medications, especially certain antidepressants, blood pressure drugs, and antihistamines, can reduce smell. Smoking, aging, and head injuries all cause smell loss independent of Alzheimer’s pathology. This diagnostic complexity means smell testing can produce false alarms.

A person with allergic rhinitis and poor smell identification scores might undergo unnecessary neurological workup, MRI scanning, and cognitive testing, only to learn that nasal saline rinses and antihistamine medication partially restored their olfactory ability and their cognition was normal throughout. The psychological impact shouldn’t be dismissed: being told you might be at high risk for dementia based on a smell test can create lasting anxiety. Additionally, smell loss is not sensitive enough or specific enough on its own to guide treatment decisions. Someone with poor smell identification and normal cognitive testing shouldn’t start taking dementia prevention drugs based solely on the smell test. The evidence doesn’t yet support that prophylactic treatment of asymptomatic people at high risk truly prevents or delays symptom onset, and medications carry their own risks. Another practical limitation: standardized smell testing requires training and isn’t universally available. The peanut butter test is widely known but less formally standardized than the UPSIT, meaning different clinicians may perform and interpret it differently.

Limitations, False Alarms, and Diagnostic Pitfalls

Current Research Advances in Olfactory Biomarkers

Recent neuroimaging studies have begun mapping specific brain regions involved in olfactory dysfunction in Alzheimer’s. Advanced techniques like functional connectivity MRI show that people with poor smell identification have abnormal communication patterns between the olfactory bulb and memory centers like the hippocampus and medial temporal lobe. This allows researchers to distinguish smell loss related to Alzheimer’s pathology from smell loss due to simple sinus obstruction or aging.

One study examined the brains of cognitively normal older adults who had poor smell identification and found accelerated brain atrophy specifically in olfactory-related regions compared to those with normal smell, even in people without cognitive symptoms. Genetic research is also exploring whether certain genetic risk factors for Alzheimer’s (particularly APOE4 genotype) interact with olfactory dysfunction to increase dementia risk. If smell loss is found to be a stronger predictor of cognitive decline specifically in genetically vulnerable individuals, it could refine targeting of preventive interventions. These advances may eventually allow doctors to distinguish between concerning olfactory decline and benign age-related smell loss, increasing the diagnostic specificity of smell testing.

The Future of Early Detection and Prevention

The ultimate promise of smell testing and other early biomarkers lies in prevention. If Alzheimer’s pathology can be detected in the brain 10 to 20 years before symptoms, there’s a window for intervention during which slowing or halting the disease might be possible. Some preventive medications are now in clinical trials specifically targeting asymptomatic people with evidence of Alzheimer’s pathology. Smell testing could help identify candidates for these trials or for lifestyle interventions like cognitive training, cardiovascular exercise, or dietary changes that may reduce dementia risk.

As our understanding of Alzheimer’s preclinical stages deepens, the role of smell testing will likely become clearer. Rather than a standalone screening tool, it will probably function as one component of a comprehensive risk assessment that includes blood biomarkers, imaging, cognitive testing, and family history. Healthcare systems that successfully implement this multimodal approach might catch Alzheimer’s at earlier, more treatable stages. For now, if you experience unexplained smell loss, especially alongside any cognitive concerns, mentioning it to your doctor makes sense. It’s an inexpensive, noninvasive hint that deeper evaluation might be warranted.

Conclusion

Smell testing represents a scientifically grounded approach to earlier Alzheimer’s detection, backed by genuine research showing the olfactory system’s connection to early Alzheimer’s pathology. The simplicity and low cost of smell testing make it an attractive screening tool, particularly when combined with other biomarkers and clinical assessment. However, the test is not yet a clinical standard for early detection, partly because smell loss has many causes and partly because not all people with smell decline develop cognitive disease.

If you’re concerned about Alzheimer’s risk, the practical next step is honest conversation with your doctor about both smell changes and any cognitive concerns, family history, or risk factors you carry. Rather than seeking smell testing as an independent predictor, think of it as one piece of information that, combined with other assessments, helps paint a more complete picture of your brain health. As research continues and blood biomarkers become more widely available, the ability to identify people at high risk during the preclinical stage will improve, and interventions designed to slow or prevent symptom onset may offer real hope.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.